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Abstract
C1q TNF Related Protein 3 (CTRP3) is a member of a family of secreted proteins that exert a
multitude of biological effects. Our initial work identified CTRP3’s promise as an effective treat-
ment for Nonalcoholic fatty liver disease (NAFLD). Specifically, we demonstrated that mice
fed a high fat diet failed to develop NAFLD when treated with CTRP3. The purpose of this cur-
rent project is to identify putative receptors which mediate the hepatic actions of CTRP3.
Methods
We used Ligand-receptor glycocapture technology with TriCEPS™-based ligand-receptor
capture (LRC-TriCEPS; Dualsystems Biotech AG). The LRC-TriCEPS experiment with
CTRP3-FLAG protein as ligand and insulin as a control ligand was performed on the H4IIE
rat hepatoma cell line.
Results
Initial analysis demonstrated efficient coupling of TriCEPS to CTRP3. Further, flow cytome-
try analysis (FACS) demonstrated successful oxidation and crosslinking of CTRP3-Tri-
CEPS and Insulin-TriCEPS complexes to cell surface glycans. Demonstrating the utility of
TriCEPS under these conditions, the insulin receptor was identified in the control dataset.
In the CTRP3 treated cells a total enrichment of 261 peptides was observed. From these
experiments 5 putative receptors for CTRP3 were identified with two reaching statistically
significance: Lysosomal-associated membrane protein 1 (LAMP-1) and Lysosome mem-
brane protein 2 (LIMP II). Follow-up Co-immunoprecipitation analysis confirmed the associ-
ation between LAMP1 and CTRP3 and further testing using a polyclonal antibody to block
potential binding sites of LAMP1 prevented CTRP3 binding to the cells.
Conclusion
The LRC-TriCEPS methodology was successful in identifying potential novel receptors for
CTRP3.
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Relevance
The identification of the receptors for CTRP3 are important prerequisites for the develop-
ment of small molecule drug candidates, of which none currently exist, for the treatment
NAFLD.
Introduction
Since the discovery of leptin by Zhang et al. [1] many secreted bioactivemolecules have been
identifiedwhich originate from adipose tissue. Thus far, over 260 unique adipose tissue derived
secreted proteins/peptides have been identified, collectively termed adipokines [2–5]. Efforts to
identify such metabolic regulators have led to the discovery of a family of secreted proteins,
designated as C1q TNF-Related Proteins, with 15 unique proteins currently identified
(CTRP1-15) [6–14]. C1q family proteins are characterized by a distinctive ‘globular domain’ of
about 140 amino acids (the gC1q domain) [14]. The CTRP proteins, adiponectin, TNF-alpha,
as well as other proteins with the C1q domain are collectively referred to as the C1q/TNF
superfamily [14–18]. Proteins within the C1q/TNF superfamily share some structural similari-
ties, but may have apposing functions [18]. To date, many unique functions have been identi-
fied for the CTRP proteins encompassing regulatory roles in metabolism, inflammation and
cell proliferation [6, 9, 15–29]. Of these proteins our lab has identified a liver specific role for
CTRP3 in preventing Nonalcoholic fatty liver disease (NAFLD) [29].
Adiponectin, the most widely studiedmember of the C1q/TNF superfamily, increases lipid
oxidation in liver and skeletal muscle [16, 30–32]. Unlike adiponectin or other C1q TNF
related proteins, we observedno direct effect of CTRP3 on skeletal muscle in vitro or in vivo [9,
29]. This implies that CTRP3 works through a novel receptor, as the three identified receptors
for adiponectin are all present in skeletal muscle [33–35]. In further support of this hypothesis
both CTRP3 and adiponectin decrease hepatic TAG accumulation, however adiponectin
reduces hepatic triglyceride levels largely through activation of AMP-activated protein kinase
(AMPK) pathways [32], whereas CTRP3 did not affect AMPK phosphorylation status [9, 29].
The finding of divergent downstream signaling pathways also argue that CTRP3 has a receptor
distinct from adiponectin. Combined, these data indicate that CTRP3 is a distinct member of
the C1q/TNF superfamily and functions through a unique receptor in liver. The receptor and
the mechanism(s) responsible for the CTRP3-induced reduction in hepatic TAG accumulation
remain unexplored.
LRC-TriCEPS™ is an promising, novel technology recently described in Nature Protocols
and Nature Biotechnology [36, 37]. First published by the lab of BerndWollscheid, TriCEPS™
is a chemoproteomic reagent coupled to a ligand of interest (CTRP3) that acts to covalently
link the ligand to the cell-based receptor [36]. This linkage protects the ligand-receptor conju-
gate from the subsequent digestion steps and peptide level purification via the biotin tag on the
TriCEPS™ molecule. The TriCEPS™ and the ligand are subsequently released through specific
enzymatic cleavage and the receptor peptides are collected and analyzed by Liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS). The LRC-TriCEPS™ technique has been vali-
dated through successful detection of known receptors, however, using this technology to
identify receptors for novel proteins is still in its infancy [36, 37].
The purpose of this study was to determine if we could successful use the LRC-TriCEPS™ to
identify novel potential receptors which mediate the hepatic effects of CTRP3. In brief, we were
able to identify five potential novel receptors using the LRC-TriCEPS™ technique.
CTRP3 Receptor Identification
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Methods
Cell culture
HEK-293T cells (Thermo fisher, GripTite 293 MSR Cell Line Cat # R79507) were cultured in
Dulbecco'sModification of Eagle'sMedium (DMEM) with 4.5 g/L glucosewithout L-glutamine
and sodium pyruvate (Corning, Cat# 15–017) supplemented with 5% (v/v) fetal bovine serum
(HyCloneTM, Cat# SH30088.03) and with antibiotic/antimycotic Solution (Corning, Cat# 30-
004-CI). HEK-293T cells were used for transfection and protein purification protocols. H4IIE
cells (H-4-II-E rat hepatoma cells, ATCC1 cat# CRL-1548™, RRID:CVCL_0284) were cul-
tured in DMEM containing 1 g/L glucose, L-glutamine, and sodium pyruvate (Corning Cat#
10–014) supplemented with 10% (v/v) fetal bovine serum (HyCloneTM, cat# SH30088.03) and
with antibiotic/antimycotic Solution (Corning, Cat# 30-004-CI). H4IIE rat hepatoma cells are
a well-established in vitro model of hepatocytes, useful for metabolic research as this cell line
mirrors the liver-like, insulin regulated glucose and lipid metabolism found in the liver [38–
40]. Further, the CTRP3 amino acid sequence is highly conserved throughout vertebrate evolu-
tion with only 4 amino acids differing between the mouse and rat orthologs and a 95% homo-
geneity betweenmouse and human [6, 9]. Therefore, we expect that the receptor and metabolic
effects of CTRP3 established in H4IIE cell line in vitro will provide insight to the actions of
CTRP3 in vivo.
Protein purification
C-terminal FLAG-Tagged mouse CTRP3 and CTRP1 were produced as describedpreviously
[9, 41]. Briefly, transient transfections were performed on HEK-293T cells using calcium phos-
phate according to standard protocols [42]. At 48 h after transfection, cells were washed and
then cultured in serum-freeOpti-MEM I medium (Invitrogen, Cat# 51985034) supplemented
with vitamin C (0.1 mg/ml; Fisher ScientificCompany, Cat# FLBP351). Supernatants were col-
lected three times, every 48 h, pooled and purified using an anti-FLAG affinity gel according to
the manufacturer's protocol (Biotool.com, Cat# B23101), and eluted with 150 μg/ml FLAG
peptide (Sigma, Cat# F4799). Dialysis was performed on purified proteins with 20 mMHepes
buffer (pH 8.0) containing 135 mMNaCl in a 10 kDa cut-off Slide-A-Lyzer dialysis cassette
(Thermo Fisher Scientific, Cat# 88252).
Immunofluorescence
For visualizationH4IIE hepatocytes were grown to confluence on Millicell EZ SLIDE (Milli-
pore Cat# PEZGS0816) in standard growth medium. The cells treated with recombinant FLAG
tagged CTRP3, CTRP1, or vehicle for 1 hr. Afterwards the cells were washed in phosphate buff-
ered saline (PBS; 137 mMNaCl, 10 mM Phosphate, 2.7 mMKCl, ph 7.2) fixed in 4% formalde-
hyde diluted in PBS for 10 minutes at 37 C, washed with PBS, and then blocked in 5% Normal
goat serum (diluted in PBS). The cells were then incubated with rabbit anti-FLAG (Cell Signal-
ing Technology Cat# 14793; RRID: AB_2572291) followed by fluorochrome-conjugated sec-
ondary antibody (Cell Signaling Technology Cat# 4412 RRID: AB_1904025). Cells were then
mounted with an anti-fade mounting mediumwith DAPI (DAPI Fluoromount-G1; South-
ernBiotech Cat# 0100–20), and immunofluorescencewas visualized [Zeiss Observer.Z1].
Fatty acid oxidation
H4IIE hepatocytes were allowed to adhere to 24-well culture plates XF24 cell culture micro-
plate (Seahorse Bioscience, Cat# 100777–004) after seeding for 2 days, according to standard
protocols (Seahorse Bioscience). Cells were pre-incubated with 5 μg/ml CTRP3 or vehicle for 1
CTRP3 Receptor Identification
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H then transferred into XF assay medium (Seahorse Bioscience, Cat# 100965–000) supple-
mented with 0.5mM sodium pyruvate and 5mM glucose before being placed into the XF24
Extracellular Flux Analyzer (Seahorse Bioscience XF24). The dosage of recombinant CTRP3
was selected based on our previous experimental observations [9], and is well within the com-
mon dosages reported within the literature of 2–30 μg/ml [9, 29, 43, 44]. Sensor cartridge of
XF24 extracellular flux assay kit (Seahorse Bioscience, Cat# 100850–001) was hydrated by load-
ing 1ml XF calibrant (Seahorse Bioscience, Cat# 100840–000) into each well in utility plate and
incubating at 37°C overnight in a non-CO2 incubator. 200uM palmitate conjugated to bovine
serum albumin (BSA) or fatty acid free BSA (vehicle control) was added in XF24 cell culture
microplate at time-points indicated. A 1 mMworking stock of palmitate (Sigma Cat# P5585)
conjugated to 0.17 mM fatty acid free BSA (Sigma Cat# A8806) was prepared according to
established protocols (Seahorse Bioscience). Briefly, 50 ml of a BSA solution (0.34 mM BSA,
150 mMNaCl, pH 7.4) was heated to 37 C and 40 ml of a palmitate solution (2.98 mM palmi-
tate, 150 mMNaCL), heated to 70 C, and was added in 5 mL increments. The combined solu-
tion was incubated at 37 C for 1 H under constant agitation, afterwards the pH was adjusted to
7.4 and final volume was adjusted to 100 mL with 150 mMNaCl). Aliquots were stored until
use at -20 C in glass vials.
Flow Cytometry
H4IIE hepatocytes were grown to confluence in 6-well plates (Corning Costar1Cat# 3516)
and then treated with/without recombinant CTRP3-FLAG as indicated.The cells were then col-
lected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit anti-FLAG antibody
(Cell Signaling Technology, Cat# 14793; RRID: AB_2572291) followed by fluorochrome-con-
jugated secondary antibody (Cell Signaling Technology, Cat# 4412; RRID:AB_1904025). Next
cells were suspended in buffer (0.5% Bovine SerumAlbumin in PBS) and analyzed for mean
fluorescent intensity (MFI) by using a FACScalibur flow cytometer with (CellQuest software,
BD Biosciences). Except for the quality control step for LRC-TriCEPS (see below), all FACS
experiments were performed three separate times in triplicate for each experiment (S1–S3
Files). For blocking experiments cells were co-incubatedwith polyclonal Lysosomal-associated
membrane protein 1 (LAMP-1) antibody (Santa Cruz BiotechnologyCat# sc-8098, RRID:
AB_2134494)
TriCEPS™-based ligand-receptor capture (LRC-TriCEPS)
In conjunction with Dualsystems Biotech AG, TriCEPS™-based ligand-receptor capture
(LRC-TriCEPS; Dualsystems Biotech, cat# P05201) was utilized to identify the putative recep-
tor for CTRP3 according to manufacturer’s directions. Briefly, 300μg recombinant
CTRP3-FLAG protein or Insulin (control ligand) was dissolved in 150 μl HEPES buffer (25
mM, pH 8.2) and 1.5 μl of the TriCEPS™ reagent was added to each sample and incubated for 2
H at 20°C under constant agitation. After incubation 1μl of each sample was removed to com-
plete a Dot blot experiment as a quality control to test for efficient TriCEPS™ coupling to the
ligands (data not shown). Three separate 50 mL tubes each containing 2x108 H4IIE Hepato-
cytes in PBS (pH 6.5) were washed and cooled to 4°C, all subsequent steps were performed at
4°C. 200 μl was collected from each tube and labeled as non-oxidized cells. Next, to mildly oxi-
dize the cell surface proteins 1.5 mMNaIO4 was added to each tube and cells were incubated at
4°C in the dark for 15 min under gentle rotation. The cells were then washed twice at 300 x g
for 5 min and then resuspended in 20 ml PBS (pH 6.5). An aliquot of ~80 μl was collected from
each tube and labeled as oxidized cells. The cells were then evenly divided into 6 separate tubes
and 50 μl of either TriCEPS™-coupled insulin or TriCEPS™-coupled CTRP3 was added to each
CTRP3 Receptor Identification
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tube and incubated for 90 min at 4°C under constant gentle agitation. An aliquot of ~80 μl was
collected from each tube and the collected samples (non-oxidized cells, oxidized cells, insulin
cells and CTRP3-FLAG cells) were analyzed by FACS to test for the crosslinking efficiencyof
the TriCEPS™-ligand complexes to the cell surface glycans using fluorochrome conjugated
streptavidin (Thermo Fisher Scientific Inc. eBioscienceCat# 11–4317). After completion of the
coupling reaction, the cells were collected and the cell pellet was sent to Dualsystems for
LC-MS/MS analysis.
LC-MS/MS analysis
The samples were analyzed on a Thermo LTQ Orbitrap XL spectrometer fitted with an electro-
spray ion source. The samples were measured in data dependent acquisition mode in a 60 min
gradient using a 10cm C18. The six individual samples in the dataset were analyzed with a sta-
tistical ANOVA model. This model assumes that the measurement error follows Gaussian dis-
tribution and views individual features as replicates of a protein's abundance and explicitly
accounts for this redundancy. It tests each protein for differential abundance in all pairwise
comparisons of ligand and control samples and reports the p-values. Next, p-values are
adjusted for multiple comparisons to control the experiment-wide false discovery rate (FDR).
The adjusted p-value obtained for every protein is plotted against the magnitude of the fold
enrichment between the two experimental conditions. Proteins are considered significant if
FC2 and adj. p-value<0.05.
Co-Immunoprecipitation (Co-IP) and Immunoblot Analysis
H4IIE hepatocytes were grown to confluence in 6-well plates (Corning Costar1Cat# 3516)
and then treated overnight with/without recombinant CTRP3-FLAG overnight. The cells were
then washed with PBS and collected in Non-denaturing lysis buffer (20 mM Tris HCl pH 8,
137 mMNaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA). Cells were incubated with con-
stant agitation for 30 minutes at 4° and then centrifuged at 10,000xg at 4°C for 10 minutes and
the supernatant was collected and protein concentration was determined via Bradford assay
(Pierce Coomassie Plus Cat# 23238). Equal amounts of protein were dilute to 500 μl final vol-
ume and used for immunoprecipitation according to manufactures directions (Bimake, Anti-
DYKDDDDK(Flag) Affinity Gel Cat# B23101). Total protein homogenate or immunoprecipi-
tate were loaded and separated on a 12%Mini-Protean1 TGXTM gel (Bio-Rad, Cat#456–
1046) and transferred to nitrocellulosemembranes (0.45 μm, Bio-Rad Cat#1620115). Mem-
branes were blocked in 2% non-fat milk and probed with primary antibodies overnight at 4°C
(Anti-LAMP1, Abcam Cat# ab24170) followed by horseradish peroxidase (HRP)-conjugated
goat anti-rabbit secondary antibody (Thermo Fisher ScientificCat# 31460, RRID:AB_228341).
Membranes were incubated with HRP Substrate (Millipore Immobilon Cat# WBKLS0100) and
chemiluminescencewas then visualizedwith FluorChem1 M imager (ProteinSimple). Preci-
sion Plus Protein™ Dual Color Standards molecular weight markers were used in all immuno-
blot analysis (BioRad Cat#161–0374).
Statistical Analysis
For analysis of flow cytometry and fatty acid oxidation, data from each experiment was nor-
malized to the control and the combined data from the three independent replicates was com-
bined and analyzed with a one-way ANOVA (flow cytometry) or repeated measure ANOVA
(fatty acid oxidation) followed by Tukey's multiple comparisons test Post hoc analysis. Statis-
tics analysis were completed by Graphpad Prizm version 6.
CTRP3 Receptor Identification
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Results
CTRP3 binds and has a physiological effect on hepatoma cells
Immunohistochemical analysis was used to demonstrate that recombinant CTRP3, but not
CTRP1 binds to H4IIE hepatocytes in vitro (Fig 1). Confirmatory experiments using flow
cytometry demonstrated a 200% increase in mean fluorescent intensity (MFI) when cells were
treated with recombinant FLAG tagged CTRP3 and probed with anti-FLAG antibodies, com-
pared with vehicle, and fluorochrome-conjugated secondary antibody alone treatments (Fig
2C). Interestingly, only a subset (~20%) of H4IIE cells stained positive for CTRP3 binding.
This may indicate that CTRP3 receptor surface expression is transient. For instance, it may be
yoked to the cell cycle or some other parameter of cellular circumstance.
The next series of experiments examined the effects of CTRP3 on hepatocyte oxygen con-
sumption to determine if the binding of CTRP3 to the hepatocytes resulted in a physiological
effect. Pre-treatment with recombinant CTRP3 (5 μg/ml) had no effect on lipid oxidation in
hepatocytes under standard conditions. However, in the presence of an excess of free fatty
acids (200 μM palmitate) there was an 24% increase in total oxygen consumption in the
CTRP3 pre-treated cells, indicating greater FFA utilization (Fig 3).
Fig 1. CTRP3 binds to hepatocytes in vitro. H4IIE hepatocytes were plated on Millicell EZ SLIDE (Millipore) and allowed to adhere for 48 H in
standard growth medium. The cells were treated with recombinant FLAG tagged CTRP3, CTRP1, or vehicle the cells were then incubated with rabbit
anti-FLAG primary antibody followed by fluorochrome-conjugated secondary antibody. Cells were then mounted with an anti-fade mounting medium
with DAPI, and immunofluorescence was visualized.
doi:10.1371/journal.pone.0164593.g001
CTRP3 Receptor Identification
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TriCEPS™-based ligand-receptor capture (LRC-TriCEPS)
An experiment with CTRP3-FLAG protein as a ligand and insulin as a control ligand was per-
formed on the H4IIE rat hepatoma cell line. Control experiments to assess the technical quality
were performed in parallel. Briefly, flow cytometry showed successful oxidation and crosslink-
ing of CTRP3-TriCEPS and Insulin-Triceps to the cell surface glycans (Fig 4A). LC-MS/MS
analysis showed a total enrichment of glycopeptides of 11% (261 peptides). Under these condi-
tions, INSR (insulin receptor) could be identified and quantified in the control dataset. From
these experiments 5 putative receptors for CTRP3 were identifiedwith two reaching
Fig 2. CTRP3 binds to hepatocytes in vitro. H4IIE hepatocytes were grown in standard media and then treated for 1 H ± CTRP3-FLAG (5 μg/
ml). The cells were then washed and collected in PBS, fixed in 4% formaldehyde, and then incubated with rabbit anti-FLAG antibody followed by
fluorochrome-conjugated secondary antibody and analyzed for mean fluorescent intensity (MFI) by flow cytometry. Representative image (20%
of points shown) of raw flow data from vehicle treated (A) or CTRP3-FLAG treated (B). C, the MFI ±CTRP3 normalized to vehicle for each
independent replicate. D, Percent of the cells that were positive from each experiment. Data for C & D are from 3 independent replicates
performed on different days with separate lots of recombinant CTRP3-FLAG protein with each replicate performed in triplicate and reported as
mean ± SD. Raw flow cytometry files are attached as supplementary data (S1 File). * p < vs. 0.0001 vehicle.
doi:10.1371/journal.pone.0164593.g002
CTRP3 Receptor Identification
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Fig 3. CTRP3 increases oxygen consumption. Cells were pre-incubated with 5 μg/ml recombinant
CTRP3 or vehicle for 1 H before being placed into the XFe24 Extracellular Flux Analyzer (Seahorse
Bioscience) and oxygen consumption rate (OCR) was determined. OCR was measured in the absence (A)
CTRP3 Receptor Identification
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statistically significance: Lysosomal-associatedmembrane protein 1 (LAMP-1) and Lysosome
membrane protein 2 (LIMP II) (Table 1 and Fig 4B). As LAMP1 was the promising candidate
further experiments were carried out focusing on LAMP1.
LAMP1 antibody prevents CTRP3 binding
To follow up the LRC-TriCEPS experiment we repeated the FACS experiments with the addi-
tion of a polyclonal antibody to LAMP1 in an attempt to disrupt the binding of CTRP3. The
co-incubation of H4IIE cells with recombinant CTRP3 and anti-LAMP1 polyclonal antibody
was found to significantly attenuate the binding of CTRP3 to H4IIE cells (Fig 5E and 5F).
CTRP3 Co-IP
We found that treatment with CTRP3 did not affect LAMP1 protein concentration in total
lysate (Fig 6C). To determine whether CTRP3 interacted with LAMP1 protein a Co-IP assay
was performed. Immunoblot analysis was able to successfully identify LAMP1 in the CTRP3
Co-precipitate and not in the FLAG peptide or buffer only treated cells, further supporting the
hypothesis that CTRP3 and LAMP1 associate in vivo (Fig 6D).
Discussion
Summary of findings
We successful showed using two different techniques that recombinant purifiedmammalian-
expressed CTRP3 protein binds to the H4IIE hepatoma cells. Further, using real-time oxygen
or after the addition of 200 μM palmitate (B) added at 15 minutes (vertical line). C, Area under the curve was
calculated (mean OCR value at each interval*time) for each treatment. Data represents the mean ± SD.
Data represents pooled data from 3 independent experiments each performed in triplicate, *p < 0.05 vs.
vehicle + palmitate.
doi:10.1371/journal.pone.0164593.g003
Fig 4. H4IIE rat hepatoma cells were treated with TriCEPs conjugated to Insulin or CTRP3. A, The binding of ligands to cell surface
receptors was detected by Steptavidin FITC (The TriCEPS™ reagent contains biotin) and analyzed for mean fluorescent intensity (MFI).
Representative image (20% of points shown) of raw flow data from vehicle treated. B, The samples were analyzed by Mass spectrometry
(Dualsystems Biotech, AG) and the adjusted p-value (ANOVA, adjusted for multiple comparisons) for the differential abundance of each protein
was plotted against the magnitude of the fold enrichment between insulin and CTRP3 samples. Proteins are considered significant if fold change
>2 and p<0.05. Two proteins (LAMP1 and LIMPII) were statistically significant. Raw data for Fig 4, S2 File.
doi:10.1371/journal.pone.0164593.g004
CTRP3 Receptor Identification
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consumption data we demonstrate that pre-conditioning cells with CTRP3 increased oxygen
consumption rates. Because electrons produced by free fatty acid (FFA) beta-oxidation enter
the electron transport chain at the level of complex 2 while those derived from glucose enter at
complex 1, a switch from glucose to FFA utilization is accompanied by higher oxygen con-
sumption rates [45, 46]. Theoretically, the switch from glucose to FFA should cause ~30%
increase in OCR [46, 47], if ATP turnover remains unchanged. The ~24% observed increase in
oxygen consumption supports previous findings that CTRP3 increases FFA oxidation in hepa-
tocytes [29].
Lastly, the LRC-TriCEPS experiments successfully identified and quantified statistically two
proteins as targets for CTRP3: LAMP1 and LIMPII. Additionally, 3 other potential candidates
were identified, and although there were not statistically quantified they were reported as puta-
tive receptors (Table 1). Follow-up experiments with an anti-LAMP1 polyclonal antibody par-
tially attenuated the binding of CTRP3 to the cells and Co-IP experiments further confirmed
that LAMP1 associates with CTRP3.
Study Limitations
Although we were successfully able to identify to potential proteins which act as the receptor to
mediate the effects of CTRP3 there are some study limitations that need to be addressed. This
study used an immortalized cell line as a model for hepatocytes. H4IIE cells were chosen
because they are a commonly used liver cell culture line that maintains characteristics of intact
liver cells and we have shown previously that CTRP3 had a physiological response in these
cells (i.e. reduced neutral lipid accumulation [29]). Further, the LRC-TriCEPS protocol
requires isolated cells and isolation of hepatocytes from intact liver requires enzymatic dissoci-
ation which by definition disrupts cell surface proteins. Future visualization and co-localization
studies using intact liver will need to be performed.Additionally, binding and lipid oxidation
experiments with primary hepatocytes also needs to be performed. Lastly, the identification of
putative receptors that are not exclusively expressed in hepatocytes still leaves open the possi-
bility that the liver-specific in vivo effects of CTRP3 [29] are mediated through indirect mecha-
nisms and not necessarily through direct actions of CTRP3 on hepatocytes.
Hepatic function of CTRP3
Previous work has shown that the novel adipokine CTRP3 has a potent biological effect on the
liver [9, 29]. Briefly, both transgenic overexpression of CTRP3 and daily administration of
recombinant CTRP3 reduced diet-induced hepatic triglyceride accumulation [29]. Further,
acute injections of recombinant CTRP3 significantly lowered hepatic gluconeogenesis upto 8 H
post injection [9]. However, the mechanism by which CTRP3 attenuates hepatic triglyceride
levels or gluconeogenesis is unknown. Due to similarity of CTRP3 and other members of the
CTRP family to adiponectin it has been suggested that the actions of all members of the CTRP
family are mediated through the adiponectin receptors: T-cadherin, and adiponectin receptors
Table 1. TriCEPS™-based ligand-receptor capture (LRC-TriCEPS).
Uniprot identifier Protein Number of peptides log2FC adj.pvalue
P14562 LAMP1 4 1.00 5.79E-05
P27615 LIMPII 2 1.06 0.035
P16391 HA12 3 0.53 0.046
D3ZQ57 D3ZQ57 2 0.50 0.046
Q66HD0 ENPL 2 1.13 0.072
doi:10.1371/journal.pone.0164593.t001
CTRP3 Receptor Identification
PLOS ONE | DOI:10.1371/journal.pone.0164593 October 11, 2016 10 / 18
Fig 5. Blocking LAMP1 suppresses CTRP3 binding. H4IIE hepatocytes were grown to confluence in standard media and
then treated for overnight ± CTRP3-FLAG (2.5 μg/well) and ± polyclonal LAMP1 antibody (10 μg/well, to block potential
CTRP3 Receptor Identification
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1 and 2 [35, 48]. However, our previous work suggests that CTRP3 works through a novel
mechanism, as unlike adiponectin, CTRP3 did not increase hepatic AMPK phosphorylation [9,
29, 32]. Moreover, we observedno effect of CTRP3 treatment in skeletal muscle, which has all
three of the known receptors for adiponectin [9, 33, 34]. Lastly, we have shown that CTRP3 but
not CTRP1 binds to hepatocytes in vitro (Fig 2), which supports our hypothesis that CTRP3 is
a distinctivemember of the C1q/TNF superfamily and functions through a unique receptor.
Functions of LAMP1 and LIMPII
LAMP1 [Uniprot identifier P14562] is also known as 120 kDa lysosomal membrane glycopro-
tein (LGP-120) and CD107 antigen-like family member A (CD107a). LAMP1 was initially
characterized as a type 1 integral lysosomal membrane glycoprotein that is found in a wide
variety of tissues (including the liver) and is commonly used as lysosomal marker [49, 50].
However more recently it has been reported that LAMP1 also shuttles to the plasma mem-
brane, indicating that it could act as a cell surface receptor [51–53]. Further, ~5% of the total
CTRP3 binding sites). The cells were then washed and collected in PBS, fixed in 4% formaldehyde, and then incubated with
rabbit anti-FLAG antibody followed by fluorochrome-conjugated secondary antibody and analyzed for mean fluorescent
intensity (MFI) by flow cytometry. A-D, Representative flow data from H4IIE hepatocytes. A MFI >100 was taken as positive
and is indicated in the flow plots with a gray bar. A, pooled cells with no primary antibody (isotype or negative control). B, cell
incubated with vehicle, C, recombinant CTRP3-FLAG protein, or D, co-incubated with recombinant CTRP3-FLAG protein
plus poly-clonal anti-LAMP1. E, Percent of the cells that were positive from each experiment. F, the MFI ± CTRP3 normalized
to vehicle for each independent replicate. Data for E & F are from 3 independent replicates performed on different days with
separate lots of recombinant CTRP3-FLAG protein with each independent replicate performed in triplicate and reported as
mean ± SD. Raw flow cytometry files are attached as supplementary data (S3 File). * p < 0.001 vs. vehicle; ** p < 0.001 vs.
CTRP3+LAMP1.
doi:10.1371/journal.pone.0164593.g005
Fig 6. Co-Immunoprecipitation (Co-IP) and Immunoblot Analysis. H4IIE cells were treated overnight with vehicle, FLAG peptide, or
recombinant FLAG tagged CTRP3 (rCTRP3). Total protein homogenate (A & C) or immunoprecipitate (B & D) were separated by SDS-page gel
and transferred to nitrocellulose membrane. A & B, after immunoblot total protein was visualize by brief incubation with Ponceau S staining
solution (5% acetic acid & 0.1% Ponceau S). C, LAMP1 in total protein homogenate was similar between treatments. D, Co-IP results showing
LAMP1 binds to CTRP3. Samples were immunoprecipated with anti-FLAG Affinity Gel followed by immunoblotting with antibodies against
LAMP1.
doi:10.1371/journal.pone.0164593.g006
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LAMP1 protein are located on the plasma membrane due to lysosomal fusion [51, 54]. The
transient nature of LAMP1 plasma membrane associate could explain why, in a theoretically
homologous cell culture population, only about 15–20% of the cells appeared to be positive for
CTRP3 binding (Figs 1 and 2). Regardless, we were able to show that pretreatment with
CTRP3 was sufficient to induce a significant increase in oxygen consumption. Although
LAMP1, in addition to LAMP2, account for ~50% of lysosomal membrane proteins [49] the
exact function for LAMP1 remains elusive, as LAMP1 knockout mice do not appear to have
any functional or structural abnormality [49, 52]. Currently, it is believed that LAMP1 is partly
responsible for maintaining lysosomal integrity and function [49], and plasma membrane
expression of LAMP1may play a role in tumor cell differentiation and metastasis [49]. The
potential role of LAMP1 in mediating hepatic lipid oxidation has not been explored.
Lysosome membrane protein 2 (LIMPII, Uniprot identifier P27615) is also known as Scav-
enger receptor class B member 2 (SCRB2), 85 kDa lysosomal membrane sialoglycoprotein
(LGP85), and as CD36 antigen-like 2. LIMPII was first discovered in a rat liver lysosomal frac-
tion [55] and accounts for ~4% of all lysomal proteins [56]. Although the presence of LIMPII
on the plasma membrane of hepatocytes has not been examined, LIMPII has been shown to be
essential in the cell-to-cell adhesion of the plasma membrane of cardiac myocytes (intercalated
discs) [57]. Although the exact function in metabolism for LIMPII is unknown the closely
related protein Scavenger receptor class B member 3 (SCARB3, also known asCD36/FAT) has
been implicated in hepatic insulin resistance [58, 59] and immunity [60], both functions impli-
cated with CTRP3. Like SCARB3, LIMPII has been shown to bind to the adhesive glycoprotein
thrombospondin-1 [56], which may help mediate cell-to-cell interactions. LIMPII is primarily
expressed in the liver, placenta, adrenal cortex and adrenal gland [50] and has already been
implicated as an internal receptor responsible for shuttling the enzyme glucocerebrosidase to
the lysosome. Glucocerebrosidasemetabolizes the sphingolipid glucocerebroside, and when
deficient results in Gaucher disease (or the excessive accumulation of the lipid molecule gluco-
cerebroside in cells (i.e. hepatocytes) [61].
Although lacking known cellular signaling functions, both LAMP1 and LIMPII are
expressed in hepatic cells, where they are potentially positioned to interact with CTRP3. Fur-
ther, both of these proteins can be found on the cell surface however, they may act as a co-
receptor for an as-yet-unidentified signaling receptor through which CTRP3 transmits meta-
bolic signals.
Summary and Conclusion
Previous work has shown that the novel adipokine CTRP3 has a potent biological effect on the
liver [9, 29]. However, the mechanism by which CTRP3 attenuates hepatic triglyceride levels is
unknown. The purpose of this study was to determine if we could successfully use the relatively
newmethodological approach, LRC-TriCEPS™ method, to identify potential receptors, which
mediate the biological effects of CTRP3.We have successfully identified two potential novel
receptors using the LRC-TriCEPS™ technique: LAMP1 and LIMPII. Although, the intracellular
signalingmechanism remain unknown the identification of the receptors for CTRP3 and other
members of this family are an important prerequisite of the development of small molecule drug
candidates that work through CTRP3 receptors to exert effects beneficial to human health.
Supporting Information
S1 Fig. Protter visualization of Identified peptides.The identified peptides of LAMP1 are
visualizedwith Protter [62]. Identified peptide sequences are signified by blue circles.
(TIF)
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S2 Fig. Protter visualization of Identified peptides.The identified peptides of LIMPII are
visualizedwith Protter [62]. Identified peptide sequences are signified by blue circles.
(TIF)
S1 File. Raw data files for Fig 2.Unaltered raw flow cytometry files for the data shown in
Fig 2.
(ZIP)
S2 File. Raw data files for Fig 4.Unaltered raw flow cytometry files and excel spreadsheet of
Mass spectrometryoutput for the data shown in Fig 4.
(ZIP)
S3 File. Raw data files for Fig 5.Unaltered raw flow cytometry files for the data shown in
Fig 5.
(ZIP)
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